Theralase Technologies (TSE:TLT) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Theralase Technologies Inc. announced that their drug Ruvidar has outperformed Acyclovir in preclinical trials against Herpes Simplex Virus 1, demonstrating more effective viral destruction. The company is now exploring partnerships and licensing as they gear up for the commercial development of Ruvidar in a market expected to reach $71.1 billion by 2032.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
